Comparison of recombinant plasminogen activator inhibitor-1 and epsilon amino caproic acid in a hemorrhagic rabbit model
- PMID: 1509411
Comparison of recombinant plasminogen activator inhibitor-1 and epsilon amino caproic acid in a hemorrhagic rabbit model
Abstract
A rabbit ear model of blood loss was developed to compare the effects of an active form of recombinant plasminogen activator inhibitor-1 (rPAI-1) with epsilon amino caproic acid (EACA) in antagonizing tissue-type plasminogen activator (r-tPA)-induced blood loss. The antagonism of both rebleeding, which occurs as a result of hemostatic plug degradation, and r-tPA-induced hemorrhage, where rabbits lose approximately 30% of their blood volume, was studied. rPAI-1 (1 mg/kg i.v.) or EACA (70 mg/kg i.v.) antagonized the rebleeding induced by r-tPA (10 micrograms kg-1 min-1) to a similar extent. In the hemorrhagic studies, rPAI-1 effectively antagonized the r-tPA-induced hemorrhage with an ED50 of 3 mg/kg i.v., while the ED50 obtained for EACA was 230 mg/kg i.v. rPAI-1 may be of value in reversing r-tPA-induced blood loss during thrombolytic therapy or in clinical situations where excessive fibrinolysis contributes to bleeding.
Similar articles
-
Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo.Thromb Haemost. 1992 Jul 6;68(1):60-3. Thromb Haemost. 1992. PMID: 1514173
-
Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits.J Clin Invest. 1989 Aug;84(2):586-91. doi: 10.1172/JCI114202. J Clin Invest. 1989. PMID: 2503540 Free PMC article.
-
The fibrinolytic system attenuates vascular tone: effects of tissue plasminogen activator (tPA) and aminocaproic acid on renal microcirculation.Br J Pharmacol. 2004 Mar;141(6):971-8. doi: 10.1038/sj.bjp.0705714. Epub 2004 Mar 1. Br J Pharmacol. 2004. PMID: 14993107 Free PMC article.
-
Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).Thromb Haemost. 1993 Aug 2;70(2):294-300. Thromb Haemost. 1993. PMID: 8236138
-
Hybrid molecules: insights into plasminogen activator function.Mol Biol Med. 1991 Apr;8(2):245-55. Mol Biol Med. 1991. PMID: 1806766 Review.
Cited by
-
Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid.Exp Ther Med. 2015 Jun;9(6):2339-2343. doi: 10.3892/etm.2015.2399. Epub 2015 Apr 1. Exp Ther Med. 2015. PMID: 26136983 Free PMC article.
-
Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding.Biomed Res Int. 2015;2015:392862. doi: 10.1155/2015/392862. Epub 2015 Mar 26. Biomed Res Int. 2015. PMID: 25883959 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous